Abnormal karyotypes in patients with NPM1-mutated AML from the Munich Leukemia Laboratory
| Patient . | Karyotype . | MRC . |
|---|---|---|
| MLD− | ||
| Aberrant 1 | 45,X,−Y[18]/46,XY[4] | − |
| Aberrant 2 | 45,X,−Y[20] | − |
| Aberrant 3 | 45,X,−Y[7]/44,X,−Y,dic(12;13)(p11;p11)[13] | + |
| Aberrant 4 | 45,X,−Y[20] | − |
| Aberrant 5 | 45,X,−Y[20] | − |
| Aberrant 6 | 46,XX,del(12)(p12)[8]/46,XX[15] | + |
| Aberrant 7 | 46,XX,del(9)(q22q34)[20] | + |
| Aberrant 8 | 46,XX,der(1)t(1;1)(p36;q12)[14]/46,XX[1] | − |
| Aberrant 9 | 47,XX,+21[4]/46,XX[16] | − |
| Aberrant 10 | 47,XX,+21[17]/46,XX[3] | − |
| Aberrant 11 | 47,XX,+21[3]/46,XX[17] | − |
| Aberrant 12 | 47,XX,+4[20] | − |
| Aberrant 13 | 47,XX,+8[6]/46,XX[4] | − |
| Aberrant 14 | 47,XX,+8[20]/46,XX[1] | − |
| Aberrant 15 | 47,XY,+4[4]/46,XY[16] | − |
| Aberrant 16 | 47,XY,+4[4]/46,XY[18] | − |
| Aberrant 17 | 47,XY,+8[14]/46,XY[6] | − |
| Aberrant 18 | 47,XY,+8[6]/46,XY[14] | − |
| Aberrant 19 | 55,XY,+X,+4,+5,+8,+10,+13,+14,+17,+18[4]/47, XY,+X[8] | + |
| Aberrant 20 | 90,XXXX,−3,+8,+8,−10,−11,−17[5]/46,XX[15] | + |
| MLD+ | ||
| Aberrant 21 | 45,X,−Y[18]/46,XY[2] | − |
| Aberrant 22 | 45,XY,−17,der(18)t(17;18)(q11;q23),del(20)(q12)[16]/ 46,XY[4] | − |
| Aberrant 23 | 46,X,−Y,+8[17]/47,X,−Y,+8,+8[3] | − |
| Aberrant 24 | 46,XX,del(9)(q22)[7]/46,XX[13] | + |
| Aberrant 25 | 46,XX,der(19)t(3;19)(q21;p13)[6]/47,XX,+8[2]/47,XX, der(19)t(3;19)(q21;p13),+8[2]/46,XX[1] | − |
| Aberrant 26 | 46,XY,del(20)(q11)[11]/46,XY[9] | − |
| Aberrant 27 | 46,XY,der(18)t(18;21)(p11;q11)[16]46,XY[4] | − |
| Aberrant 28 | 46,XY,t(3;10)(q12;q21)*[20] | − |
| Aberrant 29 | 47,XX,inv(2)(p12q21)*,+8[4]/46,XX,inv(2)(p12q21)*[16] | − |
| Aberrant 30 | 47,XY,+4[15]/46,XY[5] | − |
| Aberrant 31 | 47,XY,+8[14]/46,XY[6] | − |
| Patient . | Karyotype . | MRC . |
|---|---|---|
| MLD− | ||
| Aberrant 1 | 45,X,−Y[18]/46,XY[4] | − |
| Aberrant 2 | 45,X,−Y[20] | − |
| Aberrant 3 | 45,X,−Y[7]/44,X,−Y,dic(12;13)(p11;p11)[13] | + |
| Aberrant 4 | 45,X,−Y[20] | − |
| Aberrant 5 | 45,X,−Y[20] | − |
| Aberrant 6 | 46,XX,del(12)(p12)[8]/46,XX[15] | + |
| Aberrant 7 | 46,XX,del(9)(q22q34)[20] | + |
| Aberrant 8 | 46,XX,der(1)t(1;1)(p36;q12)[14]/46,XX[1] | − |
| Aberrant 9 | 47,XX,+21[4]/46,XX[16] | − |
| Aberrant 10 | 47,XX,+21[17]/46,XX[3] | − |
| Aberrant 11 | 47,XX,+21[3]/46,XX[17] | − |
| Aberrant 12 | 47,XX,+4[20] | − |
| Aberrant 13 | 47,XX,+8[6]/46,XX[4] | − |
| Aberrant 14 | 47,XX,+8[20]/46,XX[1] | − |
| Aberrant 15 | 47,XY,+4[4]/46,XY[16] | − |
| Aberrant 16 | 47,XY,+4[4]/46,XY[18] | − |
| Aberrant 17 | 47,XY,+8[14]/46,XY[6] | − |
| Aberrant 18 | 47,XY,+8[6]/46,XY[14] | − |
| Aberrant 19 | 55,XY,+X,+4,+5,+8,+10,+13,+14,+17,+18[4]/47, XY,+X[8] | + |
| Aberrant 20 | 90,XXXX,−3,+8,+8,−10,−11,−17[5]/46,XX[15] | + |
| MLD+ | ||
| Aberrant 21 | 45,X,−Y[18]/46,XY[2] | − |
| Aberrant 22 | 45,XY,−17,der(18)t(17;18)(q11;q23),del(20)(q12)[16]/ 46,XY[4] | − |
| Aberrant 23 | 46,X,−Y,+8[17]/47,X,−Y,+8,+8[3] | − |
| Aberrant 24 | 46,XX,del(9)(q22)[7]/46,XX[13] | + |
| Aberrant 25 | 46,XX,der(19)t(3;19)(q21;p13)[6]/47,XX,+8[2]/47,XX, der(19)t(3;19)(q21;p13),+8[2]/46,XX[1] | − |
| Aberrant 26 | 46,XY,del(20)(q11)[11]/46,XY[9] | − |
| Aberrant 27 | 46,XY,der(18)t(18;21)(p11;q11)[16]46,XY[4] | − |
| Aberrant 28 | 46,XY,t(3;10)(q12;q21)*[20] | − |
| Aberrant 29 | 47,XX,inv(2)(p12q21)*,+8[4]/46,XX,inv(2)(p12q21)*[16] | − |
| Aberrant 30 | 47,XY,+4[15]/46,XY[5] | − |
| Aberrant 31 | 47,XY,+8[14]/46,XY[6] | − |
MRC (myelodysplasia-related change) indicates which cases show cytogenetic abnormalities sufficient to diagnose acute myeloid leukemia (AML) with myelodysplasia-related features (according to World Health Organization [WHO] 200813 ); MLD+, cases with multilineage dysplasia (according to WHO 200813 ); and MLD−, cases without multilineage dysplasia (according to WHO 200813 ).
Possible constitutional chromosomal aberration.